KENALOG-10 10 mg/mL (Triamcinolone Acetonide INJECTION, SUSPENSION) 10 mg/mL

Kenalog-10 is a 10 mg/mL triamcinolone acetonide injection used for localized inflammation and pain relief. This multi-dose suspension is administered via intra-articular or intralesional routes.

Strength

10 mg/mL

Pack Size

1 VIAL, MULTI-DOSE in 1 CARTON (0003-0494-20) / 5 mL in 1 VIAL, MULTI-DOSE

Manufacturer / TM Owner

E.R. Squibb & Sons, L.L.C.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Kenalog-10 is primarily used to reduce inflammation and provide pain relief in specific areas of the body. It is often administered for conditions involving joints, such as arthritis, or localized skin lesions. The injection targets the affected area directly, making it useful for managing symptoms where oral medications may not be as effective.

Side Effects

Common effects of Kenalog-10 may include temporary relief from pain and reduced inflammation at the injection site. Some users may experience localized swelling or discomfort following administration, which typically subsides over time.

Precautions & Warnings

Kenalog-10 should be handled with care to avoid contamination. It is important to follow proper injection techniques and storage guidelines to maintain the integrity of the suspension. Always consult a healthcare provider before use.

Avoid Interactions

Kenalog-10 may interact with other medications, particularly those that affect the immune system or blood clotting. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Kenalog-10 is used to reduce inflammation and provide pain relief in specific areas of the body, such as joints or localized skin lesions.

Kenalog-10 is administered via intra-articular or intralesional injection, targeting the affected area directly.

Common effects may include temporary relief from pain and reduced inflammation at the injection site, with possible localized swelling or discomfort.

It is important to consult a healthcare provider before using Kenalog-10 with other medications, as interactions may occur.

Kenalog-10 should be stored according to the manufacturer's guidelines to maintain its effectiveness and sterility.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.